Diseases that cause nerve cells in the brain to die over time are known as neurodegenerative diseases. These cells, known as neurons, are vulnerable to DNA damage because they are highly active cells that require large amounts of energy. Neural DNA damage is a normal part of aging as changes to the DNA sequence, called mutations, build up over time. 

Previous scientists have shown that neurons from people with the neurodegenerative diseases Alzheimer’s disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) accumulate unusually high numbers of changes in the DNA sequence, called somatic mutations. However, researchers don’t know what causes the high number of mutations or whether the same process causes them in all 3 diseases. 

To answer these questions, researchers at Boston Children’s Hospital and Harvard Medical School analyzed brain tissue from people who died with and without AD, FTD, or ALS. They compared the processes that cause DNA mutations in the 3 diseases by first accessing the DNA inside individual neurons from healthy and diseased postmortem brain tissue. 

To do this, they broke apart the brain tissue and added a fluorescent marker that identified the center of each neuronal cell where DNA is housed, called its nucleus. They used a sorting machine to separate the nuclei from the rest of the cell material to access the neuron’s DNA. Using a DNA sequencing method called single-cell whole genome sequencing, the team then sequenced each neuron’s DNA to identify mutations. 

They analyzed 159 neurons from people with AD, 61 neurons from people with FTD, 77 neurons from people with ALS, and 232 neurons from healthy individuals. This allowed the team to compare the number and types of DNA mutations between diseased and control (non-diseased) neurons. The researchers found that compared to the control neurons, which typically accumulate only 200 to 300 mutations over an 80-year lifespan, neurons from all 3 diseases contained an unusually high number of 2-base-pair deletions, often exceeding 1,000 mutations per cell. 

When a biological process damages DNA, it leaves behind its own unique signature. By identifying these signatures, scientists can identify the biological process that likely caused the damage. Since these 2-base-pair deletions were so frequent in diseased neurons, the researchers wanted to know whether they were left behind by a biological process. The researchers used a machine learning algorithm to scan DNA sequences for recurring mutation patterns and identified a signature in neuronal DNA, which they named ID-4.

When the researchers compared the ID-4 signature with a database of previously characterized signatures, they found that it was associated with a DNA repair protein called TOP1. TOP1 temporarily cuts and rejoins DNA to relieve the tension that builds up during normal cellular activity. TOP1 typically detaches from the DNA after completing this process. However, if TOP1 fails to detach, it breaks one of the two DNA strands. 

To test whether abnormal TOP1 activity was breaking the DNA, the researchers isolated DNA from control and diseased neurons. They visualized the DNA on a gel, where intact DNA forms bands while broken DNA spreads out into smears. The more fragmented the DNA is, the more intense the smear appears. Using a machine that quantified the intensity of smears, the researchers found that DNA from diseased neurons produced smears that were up to 3.2 times more intense than those from control neurons. They also found that neurons with more DNA fragmentation had more ID-4 signatures. 

Based on these findings, the researchers concluded that abnormal TOP1 activity created frequent single-strand DNA breaks. They proposed that some of these breaks are repaired incorrectly, eventually leading to widespread DNA breaks in all 3 neurodegenerative diseases.

Overall, the researchers found that neurons from these 3 neurodegenerative diseases accumulated excessive DNA mutations despite differences in the disease symptoms and underlying causes. Their findings also provided evidence that abnormal TOP1 activity contributes to this mutation accumulation. Based on these findings, they stated that preventing TOP1 from becoming trapped on DNA, or improving the DNA repair process that removes trapped TOP1, could be a promising way to treat a wide range of neurodegenerative diseases.

The post Common DNA damage could cause neurodegenerative diseases appeared first on Sciworthy.

A groundbreaking study led by researchers at the University of Southern California (USC) has revealed that Alzheimer’s disease and related dementias are projected to impose an astronomical economic burden on the United States in 2026, amounting to an estimated $818 billion. This figure eclipses prior estimates as it incorporates often overlooked and nuanced costs, including the significant toll on the quality of life for those living with dementia and the substantial unpaid care provided by family members and friends. This comprehensive accounting reshapes our understanding of dementia’s societal impact, underscoring the urgency of policy innovation and resource allocation.

Traditional assessments of dementia’s economic footprint have primarily focused on direct medical and long-term care expenses. However, this USC study breaks new ground by adopting a holistic approach that integrates broader social and economic dimensions. The model includes quality of life diminishment for patients and informal caregivers, loss of income due to both the disease and caregiving responsibilities, and the extensive, unpaid labor carried out by millions of family members — a demographic often in their prime working years. This multifaceted approach allows for a more accurate reflection of the real costs dementia inflicts on society.

The study’s authors estimate that approximately 5.7 million Americans will be living with dementia in 2026, with 5.1 million of these individuals aged 65 and over. This demographic shift drives the increasing financial demands on healthcare systems and families alike. More crucially, the profound cognitive and functional decline experienced by dementia sufferers translates to a staggering $320 billion in lost quality of life, representing the single largest cost category. Care partners, often emotionally and physically strained, suffer quality-of-life costs valued at an additional $15 billion, quantifying the invisible burden that has been historically underestimated.

Unpaid caregiving, a cornerstone of dementia support, amounts to an astonishing 6.8 billion hours annually, contributed by approximately 5.2 million unpaid caregivers. This contribution is monetized at $237 billion, illustrating the massive economic value of informal care networks sustaining individuals with dementia. Long-term medical care, which includes nursing homes, home health services, and medical treatments, is projected at $222 billion. Medicare and Medicaid programs are shoulder approximately 70% of these costs, creating fiscal pressures on public health financing, while families and patients face out-of-pocket expenses near $46 billion—a significant financial stressor for many households.

Furthermore, the study incorporates lost wages, quantifying foregone earnings of $23 billion for both individuals living with dementia and their unpaid caregivers. These labor market impacts have wide-ranging implications for household financial stability and overall economic productivity. By deploying a dynamic microsimulation modeling framework and leveraging large nationally representative datasets—such as the Health and Retirement Study and administrative data from Medicare and Medicaid—the researchers have crafted a data-driven lens through which to forecast future dementia costs under various clinical and policy scenarios.

This evolving cost model is significant not only for its predictive power but for its potential to inform decision-making at multiple levels. It integrates peer-reviewed methodologies, published in a dedicated methods paper that ensures transparency in data sources, assumptions, and simulations. This methodological rigor equips policymakers, healthcare providers, and researchers with a robust platform to interrogate the efficacy of emerging treatments, changes in care delivery models, and evolving health policies. The goal is to better understand how these innovations might shift dementia’s economic and social impact.

The USC-led team’s interdisciplinary composition enhances the study’s depth and applicability. Contributors hail from diverse academic units within USC—including the Price School of Public Policy, the Mann School of Pharmacy and Pharmaceutical Sciences, the Davis School of Gerontology, and the Viterbi School of Engineering—as well as esteemed external collaborators from the Alzheimer’s Association and the University of Pennsylvania. This collaboration has generated a model enriched by real-world insights from people with mild cognitive impairment and their care partners, gathered through Alzheimer’s Association panels. Their lived experiences add critical context often absent from purely quantitative analyses.

In parallel with advances in medical science, this research dovetails with promising trends in dementia detection and management. FDA-approved blood tests now allow for the pre-symptomatic identification of Alzheimer’s pathology, while emerging therapeutics show potential in slowing disease progression. Innovative care models focused on keeping individuals at home for longer durations while supporting family caregivers further signal a paradigm shift in dementia care. This study’s comprehensive cost framework can serve to evaluate the economic and societal ripple effects of such innovations, offering a valuable forecasting tool amid the rapidly changing landscape.

Lead researcher Julie Zissimopoulos emphasizes that accurate, comprehensive cost assessments are vital for allocation of resources in the face of a growing dementia population. This modeling approach allows for simulations that address critical questions, such as how slow-progressing treatments could improve quality of life or reduce nursing home demand, yielding insights needed for smarter, evidence-based policymaking. For example, understanding potential reductions in caregiving burden or shifts in out-of-pocket expenses can guide investment priorities across public health and social services sectors.

Moreover, the dynamic microsimulation approach employed by the study captures longitudinal impacts on individual trajectories, accounting for how health interventions at earlier disease stages might alter future care needs and economic costs. By continuously updating the model with new data inputs and methodological enhancements, the USC team ensures that their projections remain responsive to evolving clinical knowledge and demographic trends, positioning the cost estimates as authoritative inputs for strategic planning.

A particularly striking takeaway is the valuation of informal caregiving, which emphasizes the critical yet underappreciated role family and friends play in sustaining the dementia-affected population. The emotional, physical, and financial strain borne by these caregivers often goes unrecognized in policy dialogues. Quantifying these costs helps to illuminate the hidden layers of dementia’s societal toll, strengthening the argument for supportive interventions, caregiver resources, and systemic reforms to alleviate their burden.

Dana Goldman, founding director of the USC Schaeffer Institute, highlights that understanding the expanding economic footprint of dementia is fundamental to harnessing the full potential of scientific and care innovations. As Alzheimer’s disease and related dementias continue to challenge health systems globally, this study outlines a crucial framework for evaluating the interplay between emerging therapeutics, care delivery, and economic sustainability. It advocates for data-driven policies that adapt to and capitalize on these transformative changes.

This comprehensive analysis of dementia’s economic burden thus represents a critical step forward in the public health and policy arenas. Its nuanced incorporation of quality-of-life metrics, unpaid caregiving, lost earnings, and formal healthcare expenses paints a detailed portrait of the multifaceted costs dementia imposes. As American society confronts a rapidly aging population, these findings serve as a clarion call to address the broad spectrum of dementia’s impact, ensuring informed strategies to mitigate its profound human and economic consequences.

Subject of Research: Economic Impact of Alzheimer’s Disease and Related Dementias
Article Title: The 2026 U.S. Cost of Dementia: A Comprehensive Model Accounting for Quality of Life and Informal Caregiving
News Publication Date: 24 June 2026
Web References: https://schaeffer.usc.edu/cost-of-dementia-model/; https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71480
References: Zissimopoulos, J., et al. (2026). Comprehensive cost modeling of Alzheimer’s disease and related dementias. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, doi:10.1002/alz.71480
Image Credits: USC Schaeffer Center for Health Policy & Economics

Keywords: Dementia, Alzheimer’s disease, Economic burden, Quality of life, Informal caregiving, Health care costs, Lost wages, Policy modeling, Aging population, Health economics, Microsimulation

Often hailed as “the window to the soul,” the human eye has long fascinated scientists and philosophers alike. However, beyond its poetic allure, emerging research suggests that the eyes provide a vital window into the health of the brain. A groundbreaking new study spearheaded by the University of Florida’s biomedical engineering department has unveiled a transformative approach to predicting Alzheimer’s disease risk factors by analyzing retinal photographs with cutting-edge deep learning algorithms. This development promises to revolutionize early detection and intervention for one of the most devastating neurodegenerative diseases.

Traditionally, diagnosing Alzheimer’s disease has been a challenge due to its insidious onset and prolonged development over decades. Most diagnostic protocols focus on detecting the disease in its later stages, by which time significant, irreversible brain damage has already occurred. Recognizing this limitation, Dr. Ruogu Fang and her interdisciplinary team leveraged advances in artificial intelligence and biomedicine to explore the retina—a part of the central nervous system accessible via non-invasive imaging—as a potential biosensor for Alzheimer’s risk.

The study capitalized on a rich database of over 40,000 retinal images collected from the UK Biobank, a comprehensive health resource with longitudinal patient data. Retinal photography is commonly conducted during routine eye exams, diabetes management, glaucoma monitoring, and cataract assessments. By harnessing these widely available, inexpensive images, the research team circumvented the need for costly, invasive, or logistically complex diagnostic tools such as MRI or PET scans, thus holding promise for scalable, population-wide screening.

Employing deep learning, a subset of machine learning characterized by neural networks modeled after the human brain, the researchers developed an AI framework that scrutinized retinal morphology. This model was able to discern subtle variations in retinal arteries, veins, and the optic nerve head, features imperceptible to the human eye but correlated strongly with known risk factors for Alzheimer’s disease. Such morphological markers serve as proxies for neurovascular health, which is crucial given Alzheimer’s recognized association with vascular impairment.

One of the most striking revelations of this research was the model’s capacity not only to predict intrinsic biological traits such as sex and blood pressure but also modifiable lifestyle factors that influence Alzheimer’s risk. The AI effectively inferred behaviors like smoking, alcohol consumption, and even insomnia from retinal images alone. This objective measurement circumvents the notorious unreliability of self-reported lifestyle data, often plagued by bias and inaccuracies, thereby enriching risk assessment precision.

As Dr. Fang points out, retinal morphology functions less like a mere clinical questionnaire and more like an integrative biological sensor reflecting a cumulative lifetime burden of neurovascular and lifestyle insults. This conceptual shift underscores the retina’s role in encapsulating decades of physiological data, transforming retinal imaging into a powerful tool for capturing both present health and future vulnerability.

Furthermore, the implications extend beyond risk prediction. Identifying individuals with early signs of retinal changes could trigger timely clinical interventions long before cognitive symptoms manifest. Such preclinical detection enables the implementation of protective lifestyle adjustments, pharmacological therapies, or cognitive training programs designed to delay or mitigate Alzheimer’s progression.

The pioneering work built on previous findings from Fang’s group that demonstrated retinal images’ utility in detecting active Alzheimer’s disease cases. However, this new model pioneers the field by focusing on prodromal markers and risk factors instead of established dementia, bridging a critical gap in neurodegenerative diagnostics.

Importantly, the use of retinal photographs democratizes neurovascular health monitoring. Since retinal imaging is non-invasive, accessible, and affordable, it offers the prospect of integrating brain health assessment into routine eye care, thus expanding preventive neurology beyond specialized clinical settings.

This research also exemplifies the synergy between computational science and biomedical engineering. By combining sophisticated image analysis algorithms with large-scale patient data, it transcends traditional diagnostic constraints, marrying technology with medicine in a profoundly impactful manner.

While challenges remain, including the need for further validation across diverse populations and integration with other biomarkers, this study sets a new paradigm for early Alzheimer’s disease risk stratification. The possibility of preemptive interventions guided by retinal AI analysis heralds a future where the devastating trajectory of Alzheimer’s may be altered through timely and personalized healthcare.

In summary, the novel application of deep learning to retinal photographs opens an unprecedented window into brain health, heralding a new era of precision neurodiagnostics. It moves us closer to the long-sought goal of identifying Alzheimer’s risk decades in advance, fostering opportunities for early intervention and ultimately, better patient outcomes.

Subject of Research: People

Article Title: Prediction of Alzheimer’s disease risk factors from retinal images via deep learning: Development and validation of biologically relevant morphological associations in the UK Biobank

News Publication Date: 16-Jun-2026

Web References:
DOI: 10.1177/13872877261457650

Keywords

Alzheimer’s disease, Neurodegenerative diseases, Neurological disorders, Eye, Retina, Artificial intelligence, Image analysis, Deep learning, Biomedical engineering, Neurovascular integrity, Retinal biomarkers, Predictive modeling

A groundbreaking fluorescent reporter enabling real-time visualization of biologically active iron and oxygen at the single-cell level inside living organisms has been developed by researchers at the Institute of Science Tokyo. This revolutionary tool, named LiON (labile iron and oxygen notifier), ushers in a new era for cellular biology by offering unprecedented insight into the dynamic interplay and distribution of these essential elements within living tissues. Published in the esteemed journal Cell Reports Methods, this innovation promises to transform the study of fundamental physiological processes and complex diseases, from oncology and liver pathology to neurodegenerative disorders and aging.

Iron and oxygen are indispensable to cellular function, acting as core contributors to energy production, metabolic regulation, and DNA synthesis. Despite their vital roles, maintaining the delicate balance and spatial distribution of labile ferrous iron and reactive oxygen species remains critical, as disruptions often lead to cellular damage and disease. Historically, the challenge has been the absence of imaging tools capable of monitoring these elements within living cells at sufficient resolution, particularly differentiating biologically active forms from inert reservoirs.

Traditional methods of detecting iron, such as histochemical staining or mass spectrometry, require fixed tissue samples, offering only static snapshots devoid of temporal context. Although advanced clinical imaging modalities like magnetic resonance imaging enable in vivo iron mapping, they lack cellular resolution and fail to discriminate between active and stored iron pools. This limitation impairs the ability to study cellular heterogeneity and microenvironmental influences critical to disease pathogenesis.

To bridge this gap, the team led by Professor Toshiro Moroishi and doctoral researcher Ayato Maeda ingeniously exploited the iron- and oxygen-sensitive regulatory domain of FBXL5, a protein known to undergo degradation in low-iron and low-oxygen conditions. By genetically fusing this domain to a red fluorescent protein while coupling it with a stable green fluorescent protein, they engineered a ratiometric biosensor. Variations in red-to-green fluorescence ratios directly reflect intracellular labile iron and oxygen levels, enabling precise, quantitative assessments at single-cell resolution in living tissues.

Generating transgenic mice expressing LiON, the investigators revealed remarkable gradients and heterogeneity in iron and oxygen distribution across various organs and within homogeneous cell populations. For instance, they identified spatially distinct iron accumulation proximal to portal veins in the liver, highlighting areas susceptible to oxidative stress and metabolic dysfunction. These nuanced observations suggest complex regulatory mechanisms governing iron homeostasis that could not previously be elucidated in vivo.

Beyond fundamental biology, the capacity to monitor labile iron and oxygen in living systems has profound clinical implications. Iron dysregulation and hypoxia are hallmarks of cancer progression, neurodegeneration, and age-related tissue decline. The ability to dynamically track these parameters within specific cell types allows for the investigation of pathophysiological processes at an unprecedented scale, facilitating the development and evaluation of targeted therapies.

Importantly, the modular genetic design of LiON enables conditional activation in defined tissues or cell populations using well-established genetic tools. This versatility empowers researchers to tailor investigations according to disease models or biological questions, drastically expanding the utility of this fluorescent reporter across scientific disciplines. It also paves the way for high-throughput screening approaches and longitudinal studies previously unattainable.

Technically, the LiON sensor leverages competitive degradation pathways mediated by FBXL5’s hemerythrin-like domain, which senses iron and oxygen availability to regulate protein stability. When iron and oxygen are sufficient, FBXL5 remains stable, maintaining the red fluorescence. Under conditions of deficiency, FBXL5 is degraded, reducing red fluorescence and shifting the fluorescence ratio. By normalizing against stable green fluorescence, this ratiometric approach cancels out confounding factors such as expression levels or photobleaching, ensuring robust quantification.

Further development of LiON may enable integration with multiphoton or super-resolution microscopy, amplifying the ability to investigate cellular metabolism and microenvironmental niches in unprecedented detail. Moreover, its application in live imaging models can accelerate translational research by offering real-time insights into therapeutic interventions and disease progression, a vital step toward precision medicine.

The researchers emphasize that understanding heterogeneity in iron and oxygen management at the single-cell level will clarify diverse cellular responses within tissues, facilitating the identification of vulnerable or resistant cell populations. This information is invaluable for unraveling mechanisms underpinning complex diseases, optimizing drug delivery, and minimizing off-target effects.

As the first fluorescent reporter capable of in vivo, single-cell resolution imaging of labile iron and oxygen, LiON represents a transformative leap forward. The integration of this tool into mainstream biomedical research has the potential to catalyze breakthroughs spanning from fundamental cell biology to clinical therapeutics, establishing a new paradigm in the visualization and understanding of elemental biology.

In the words of Professor Moroishi, “LiON opens a window into cellular microenvironments that were previously invisible, enabling us to observe and quantify critical biochemical landscapes that dictate health and disease. We anticipate that this technology will become an indispensable asset across many branches of life science research.”

With the establishment of the Institute of Science Tokyo, a visionary new institution formed through the union of Tokyo Medical and Dental University and Tokyo Institute of Technology, this breakthrough exemplifies a commitment to pioneering innovative science aimed at enhancing human well-being. The convergence of multidisciplinary expertise and cutting-edge technology exemplified by LiON underscores the promise of collaborative research to address some of the most pressing biomedical challenges of our time.

Subject of Research: Animals
Article Title: In vivo visualization of bioactive iron and oxygen using LiON, the labile iron and oxygen notifier
News Publication Date: 8-May-2026
Web References: DOI: 10.1016/j.crmeth.2026.101431
Image Credits: Institute of Science Tokyo
Keywords: Life sciences, Cell biology, Fluorescent proteins, Biomolecules, Biochemistry, Iron, Oxygen, Human health, Diseases and disorders, Neurodegenerative diseases, Cancer research, Clinical medicine